Qiagen announced that the FDA has cleared the QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results
- Qiagen enters CRADA with FBI for QIAcuity digital PCR devices
- Qiagen Exceeds Q1 Expectations, Affirms 2024 Outlook
- Qiagen Reports Q1 2024 Financial Results
- Qiagen sees FY24 adjusted EPS $2.10, consensus $2.11